Skill Level  5

Relevance:5 Technical Level:1

Page Synopsis: The big hope

page 69 OCD > KETAMINE

page 68

page 70

Certain psychotropics take advantage of neuroplasticity to 'rewire' regional and synaptic connections as well as encourage and spur new white and grey matter growth. Psilopcybin and Lithium are two such agents, for example.

Combined with attitude shifts, consulting therapies and proper diet and exercise habits there is much that can be done to alleviate the symptoms and expressions of OCD

 

https://www.mindbloom.com

New Clients $89 / week billed monthly for 3 months

6 Ketamine Treatments

1 Bloombox

2 Psychiatric Clinician Consults

3 Guide Sessions (1 Prep / 2 Integration)

Unlimited Group Integration Sessions

Unlimited Messaging

Returning Clients $59 / week billed monthly for 3 months

6 Ketamine Treatments

1 Psychiatric Clinician Consult

Unlimited Group Integration Sessions

Unlimited Messaging

92% reported improvement in DEPRESSION

90% reported improvement in ANXIETY

 

Ketamine is most commonly administered in the dose of 0.5 mg/kg, but some patients may respond to doses as low as 0.1 mg/kg, and others may require up to 0.75 mg/kg. The ketamine dose is conventionally administered across 40 minutes; however, safety and efficacy have been demonstrated in sessions ranging between 2 and 100 minutes in duration. Bolus administration is safe and effective when the drug is administered intramuscularly or subcutaneously. Whereas the intravenous route is the most commonly employed, safety and efficacy have been described with other routes of administration, as well; these include oral, sublingual, transmucosal, intranasal, intramuscular, and subcutaneous routes. Patients may receive a single session of treatment or a course of treatment during the acute phase, and treatment may rarely be continued for weeks to years to extend and maintain treatment gains in refractory cases. When so extended, the ideal frequency is perhaps best individualized wherein ketamine is dosed a little before the effect of the previous session is expected to wear off.

https://pubmed.ncbi.nlm.nih.gov/28749092

 

“no clear or consistent evidence” that ketamine at the two lowest doses (0.1mg/kg and 0.2mg/kg) would generate a rapid antidepressant effect in treatment-resistant patients. But at the two higher doses tested – 0.5mg/kg and 1.0mg/kg – ketamine was found to “provide significant symptom amelioration within a few hours.”

https://www.bbrfoundation.org/content/seeking-optimal-dose-ketamines-short-term-rapid-antidepressant-effects

clinical evidence that has shown how ketamine works to produce antidepressant effects in those with treatment-resistant depression (TRD). These studies have used a common subanesthetic dose of 0.5 mg/kg over a period of 40 minutes when administered through an IV. An outpatient study from 2018, published in Molecular Psychiatry, recently added onto this body of research in order to find the optimal dose for antidepressant effects in those with TRD. They found that single IV doses of ketamine of 0.5 mg/kg and 1 mg/kg proved to be more effective than an active placebo in reducing depression over a 3-day period.

https://www.resetketamine.com/blog/2019/2/25/standard-amp-high-dose-ketamine-infusions-in-treatment-resistant-depression

 

 

page 69 OCD > KETAMINE

page 68

page 70

sitemap click links below

Click 1

Click 2

Click 3